DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Bepreve (Bepotastine Besilate) - Summary



BEPREVE (bepotastine besilate ophthalmic solution) 1.5% is a sterile, topically administered drug for ophthalmic use. Each mL of BEPREVE contains 15 mg bepotastine besilate.

BEPREVE® (bepotastine besilate ophthalmic solution) 1.5% is a histamine H1 receptor antagonist indicated for the treatment of itching associated with signs and symptoms of allergic conjunctivitis.

See all Bepreve indications & dosage >>


Published Studies Related to Bepreve (Bepotastine)

Efficacy of bepotastine besilate ophthalmic solution 1.5% for seasonal allergic conjunctivitis: a randomized, placebo-controlled, natural exposure, clinical trial. [2013]
Allergic conjunctivitis (AC) affects an estimated 20% of the population in the Western world, with a large fraction suffering due to seasonal or perennial allergen exposures. Bepotastine besilate ophthalmic solution (BBOS) 1.5%, a dual-acting histamine (H(1)) receptor antagonist and mast cell stabilizer, is indicated for itching associated with AC...

Bepotastine besilate ophthalmic solution for the relief of nonocular symptoms provoked by conjunctival allergen challenge. [2010]
allergen challenge (CAC), a clinical model of allergic conjunctivitis... CONCLUSIONS: The 1.5% bepotastine besilate formulation produced statistically

Multicenter clinical evaluation of bepotastine besilate ophthalmic solutions 1.0% and 1.5% to treat allergic conjunctivitis. [2010]
clinical trial... CONCLUSIONS: Bepotastine besilate ophthalmic solutions 1.0% and 1.5% both

Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children. [2009]
adults and children... CONCLUSIONS: In this CAC model of allergic conjunctivitis in adults and children,

Effects of bepotastine, cetirizine, fexofenadine, and olopatadine on histamine-induced wheal-and flare-response, sedation, and psychomotor performance. [2004]
Although many antihistamines are now in clinical use, few studies directly compare their pharmacodynamic and sedative activities in humans in vivo. We designed a double-blind, placebo-controlled, crossover study to compare the inhibitory effects of bepotastine, cetirizine, fexofenadine, and olopatadine on histamine-induced flare-and-wheal response...

more studies >>

Clinical Trials Related to Bepreve (Bepotastine)

Use of BEPREVE (Bepotastine Besilate Ophthalmic Solution) 1.5% for Allergic Conjunctivitis and Contact Lenses [Enrolling by invitation]
The purpose of this study is to assess if BEPREVE (bepotastine besilate ophthalmic solution) 1. 5% will have an effect on contact lens wear in patients with contact lens intolerance due to allergic conjunctivitis.

Comparing Patient Satisfaction With Pataday or Bepreve [Completed]
The purpose of this study is to compare patient satisfaction with Pataday (Olopatadine hydrochloride 0. 2%) one daily (QD) and Bepreve (Bepotastine besilate ophthalmic solution 1. 5%) two times a day (BID).

The Evaluation of Bepreve on the Measurement of Wheal and Flare Response From Histamine Skin Prick Testing [Completed]
To evaluate the effect of BEPREVE compared to a REFRESH Tears Lubricant eye drop on the measurement of the wheal and flare from histamine skin prick testing. This is an open label, two-week, post-marketing study conducted on histamine responsive patients.

Bepreve vs. Alrex in Subjects With Moderate to Severe Allergic Conjunctivitis [Completed]
Allergic conjunctivitis (AC) afflicts approximately 20% of the US population. Typically, patients manifest symptoms in the spring, summer and fall, when airborne allergens are at their peak. Patients may also be afflicted year-round, if sensitive to allergens such as dust mites or pet dander. Signs and symptoms of allergic conjunctivitis are conjunctival hyperemia, ocular itching, conjunctival and eyelid edema, papillary hypertrophy, tearing and burning. This is a randomized clinical study to evaluate the efficacy of Bepreve« (bepotastine besilate 1. 5% ophthalmic solution) compared to Alrex┬« (loteprednol etabonate 0. 2%) in the treatment of moderate to severe allergic conjunctivitis in patient over the age of 18 years. The study will be a two-week study with four visits. Ocular signs (eye redness( and symptoms (itching) will be monitored as outcome variables.

A Confirmatory Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis [Completed]
The objectives of this study are: to confirm the superiority of TAU-284 over placebo after two weeks of administration to pediatric patients with perennial allergic rhinitis, and to investigate the dose response, safety, and plasma concentrations of TAU-284.

more trials >>

Reports of Suspected Bepreve (Bepotastine) Side Effects

Product Taste Abnormal (3)Drug Ineffective (2)Drug Hypersensitivity (2)Throat Irritation (2)Eyelid Oedema (1)Pruritus (1)Drug Ineffective FOR Unapproved Indication (1)Upper-Airway Cough Syndrome (1)Expired Drug Administered (1)Headache (1)more >>

Page last updated: 2014-11-30

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017